Inactive Instrument

Other languages Oncobiologics Inc Nasdaq

Equities

US68235M2044

End-of-day quote Nasdaq Other stock markets
- ^USD	-

May. 28	Outlook Therapeutics Granted EU Marketing Authorization for Lytenava to Treat Wet AMD	MT
May. 28	Outlook Therapeutics, Inc. Receives European Commission Marketing Authorization for LYTENAVA? (bvacizumab grapa) for the Treatment of Wet AMD	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Outlook Therapeutics Granted EU Marketing Authorization for Lytenava to Treat Wet AMD	May. 28
Outlook Therapeutics, Inc. Receives European Commission Marketing Authorization for LYTENAVA? (bvacizumab grapa) for the Treatment of Wet AMD	May. 28
Outlook Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	May. 15
Outlook Therapeutics Submits Marketing Application for Wet Age-related Macular Degeneration Therapy in UK	May. 13
Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application for ONS-5010 as a Treatment for Wet AMD	May. 13
Outlook Therapeutics Shares Rise After BTIG Upgrade	Mar. 27
Outlook Therapeutics Reports Secondary Share Offering	Mar. 25
Sector Update: Health Care Stocks Ease Late Afternoon	Mar. 22
Sector Update: Health Care Stocks Ease Friday Afternoon	Mar. 22
Sector Update: Health Care Stocks Steady Pre-Bell Friday	Mar. 22
Outlook Therapeutics Gets EMA Panel Positive Opinion for Wet AMD Treatment -- Shares Rise Pre-Bell	Mar. 22
Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	Mar. 22
Madrigal Pharmaceuticals : Super Micro Computer, Madrigal, Tencent... les valeurs à suivre aujourd'hui à Wall Street -	Mar. 19
Outlook Therapeutics lève 60 millions de dollars pour l'approbation de son bevacizumab	Mar. 19
Outlook Therapeutics Shares Climb Following Upgrade by Chardan	Feb. 15
Outlook Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 14
Outlook Therapeutics Doses First Patient in Eye Disease Study	Jan. 31
Outlook Therapeutics, Inc. Doses First Subject in Norse Eight	Jan. 31
Sector Update: Health Care Stocks Decline Late Afternoon	Jan. 23
Sector Update: Health Care Stocks Softer Tuesday Afternoon	Jan. 23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Oncobiologics Inc Nasdaq

Equities

US68235M2044

Other languages

Filters